Document:

Document

Exhibit 10.3

SECOND AMENDMENT TO

CREDIT AGREEMENT 
DATED AS OF
NOVEMBER 2, 2020

AMONG

RATTLER MIDSTREAM LP,
AS PARENT,
RATTLER MIDSTREAM OPERATING LLC,
AS BORROWER,

WELLS FARGO BANK, NATIONAL ASSOCIATION,
AS ADMINISTRATIVE AGENT,

THE LENDERS PARTY HERETO, AND
WELLS FARGO SECURITIES, LLC,
CREDIT SUISSE SECURITIES (USA) LLC,
JPMORGAN CHASE BANK, N.A., AND
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED,
AS JOINT LEAD ARRANGERS AND JOINT BOOKRUNNERS

        

This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of November 2, 2020, is among: Rattler Midstream LP, a Delaware limited partnership (the “Parent”); Rattler Midstream Operating LLC, a Delaware limited liability company (the “Borrower”); each of the undersigned guarantors (together with the Parent, the “Guarantors”); each of the Lenders (as such term is defined in the Credit Agreement referred to below) party hereto; and Wells Fargo Bank, National Association, as administrative agent for the Lenders (in such capacity, together with its successors in such capacity, the “Administrative Agent”).
R E C I T A L S
A.    The Parent, the Borrower, the Administrative Agent, and the Lenders are parties to that certain Credit Agreement, dated as of May 28, 2019 (as amended and supplemented prior to the date hereof, the “Credit Agreement”), pursuant to which the Lenders have made certain credit available to and on behalf of the Borrower.
B.    The Borrower has requested and the Lenders signatory hereto have agreed to amend certain provisions of the Credit Agreement as set forth herein.
C.    Now, therefore, to induce the Administrative Agent and the Lenders to enter into this Amendment and in consideration of the premises and the mutual covenants herein contained, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
Section 1.     Defined Terms.  Each capitalized term used herein but not otherwise defined herein has the meaning given such term in the Credit Agreement as amended by this Amendment.  Unless otherwise indicated, all section references in this Amendment refer to sections of the Credit Agreement.
Section 2.    Amendments to Credit Agreement.  In reliance on the representations, warranties, covenants, and agreements contained in this Amendment, and subject to the satisfaction of the conditions precedent set forth in Section 3 hereof, the Credit Agreement is hereby amended, effective as of the Amendment Effective Date (as defined below), as follows:
2.1    Amendments to Section 1.02.
(a)    The following definitions are hereby amended and restated in their entirety to read as follows:
“Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.

“Bail-In Legislation” means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is 
1

        

described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom,  Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings). 

“EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.
“Loan Documents” means this Agreement, the First Amendment, the Second Amendment, the Notes, the Letter of Credit Agreements, the Letters of Credit, and the Security Instruments.

“Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority  under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution  or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.
(b)    The following definitions are hereby added where alphabetically appropriate to read as follows:
“Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.
“Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.
“Second Amendment” means that certain Second Amendment to Credit Agreement, dated as of the Second Amendment Effective Date, by and among the Parent, the Borrower, the other Guarantors party thereto, the Administrative Agent, and the Lenders party thereto.
“Second Amendment Effective Date” means November 2, 2020.
2

        

“UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended form time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
“UK Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.
2.2    Amendments to Section 9.04(a). Section 9.04(a) of the Credit Agreement is 
hereby amended by (a) deleting the reference to “and” at the end of clause (viii) therein, (b) replacing the reference to “.” with “; and” at the end of clause (ix) therein and (c) adding a new clause (x) thereto immediately following clause (ix) thereof to read as follows:

(x)    commencing on the Second Amendment Effective Date, (1) the Parent may make Restricted Payments other than dividends and distributions in an aggregate amount not to exceed $200,000,000; provided that both prior to and after giving pro forma effect thereto (including any Borrowings made in connection with any such Restricted Payment), (A) no Default or Event of Default has occurred and is continuing, (B) the Consolidated Total Leverage Ratio does not exceed 3.00 to 1.00, and (C) Availability is equal to or greater than $400,000,000 and (2) the Borrower may make Restricted Payments to the Parent.
2.3    Amendment to Section 12.17.  Section 12.17 of the Credit Agreement is hereby amended and restated in its entirety to read as follows: 
Section 12.17    Acknowledgement and Consent to Bail-In of Affected Financial Institutions.  Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)    the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
(b)    the effects of any Bail-in Action on any such liability, including, if applicable:
(i)    a reduction in full or in part or cancellation of any such liability;
3

        

(ii)    a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected  Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or
(iii)    the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of the applicable Resolution Authority.
Section 3.    Conditions Precedent.  This Amendment shall become effective on the date (such date, the “Amendment Effective Date”) when each of the following conditions is satisfied (or waived in accordance with Section 12.02 of the Credit Agreement):
3.1    The Administrative Agent shall have received from Lenders constituting Majority Lenders, the Guarantors, and the Borrower, counterparts (in such number as may be requested by the Administrative Agent) of this Amendment signed on behalf of such Person.
3.2    The Administrative Agent and the Lenders shall have received all fees and other amounts due and payable on or prior to the date hereof, including, to the extent invoiced, reimbursement or payment of all documented out-of-pocket expenses required to be reimbursed or paid by the Borrower under the Credit Agreement.
3.3    No Default shall have occurred and be continuing as of the date hereof, after giving effect to the terms of this Amendment.
The Administrative Agent is hereby authorized and directed to declare this Amendment to be effective when it has received documents confirming or certifying, to the satisfaction of the Administrative Agent, compliance with the conditions set forth in this Section 3 or the waiver of such conditions as permitted in Section 12.02 of the Credit Agreement.  Such declaration shall be final, conclusive and binding upon all parties to the Credit Agreement for all purposes.
Section 4.    Miscellaneous.
4.1    Confirmation.  The provisions of the Credit Agreement (as amended by this Amendment) shall remain in full force and effect following the effectiveness of this Amendment.
4.2    Ratification and Affirmation; Representations and Warranties.  Each of the Guarantors and the Borrower hereby (a) ratifies and affirms its obligations under, and acknowledges its continued liability under, each Loan Document to which it is a party and agrees that each Loan Document to which it is a party remains in full force and effect as expressly amended hereby and (b) represents and warrants to the Lenders that as of the date hereof, after giving effect to the terms of this Amendment:
4

        

(i)    all of the representations and warranties contained in each Loan Document to which it is a party are true and correct in all material respects (or, if already qualified by materiality, Material Adverse Effect or a similar qualification, true and correct in all respects), except to the extent any such representations and warranties are expressly limited to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (or, if already qualified by materiality, Material Adverse Effect or a similar qualification, true and correct in all respects) as of such specified earlier date;
(ii)    no Default or Event of Default has occurred and is continuing; and
(iii)    no event or events have occurred which individually or in the aggregate could reasonably be expected to have a Material Adverse Effect.
4.3    Counterparts.  This Amendment may be executed by one or more of the parties hereto in any number of separate counterparts, and all of such counterparts taken together shall be deemed to constitute one and the same instrument.  Delivery of this Amendment by facsimile or electronic transmission shall be effective as delivery of a manually executed counterpart hereof.
4.4    NO ORAL AGREEMENT.  THIS AMENDMENT, THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS EXECUTED IN CONNECTION HEREWITH AND THEREWITH REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT UNWRITTEN ORAL AGREEMENTS OF THE PARTIES.  THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.
4.5    GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
4.6    Payment of Expenses.  To the extent required pursuant to Section 12.03 of the Credit Agreement, the Borrower agrees to pay or reimburse the Administrative Agent for all of its reasonable out-of-pocket expenses incurred in connection with this Amendment, any other documents prepared in connection herewith and the transactions contemplated hereby, including, without limitation, the reasonable fees, charges and disbursements of counsel to the Administrative Agent.
4.7    Severability.  Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
5

        

4.8    Successors and Assigns.  This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.
4.9    Loan Document.  This Amendment is a Loan Document.
[SIGNATURES BEGIN NEXT PAGE]

6

        

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first written above.
												
	BORROWER:		RATTLER MIDSTREAM OPERATING LLC
				
				
			By:	/s/ Teresa L. Dick
			Name:	Teresa L. Dick
			Title:	Chief Financial Officer, Executive Vice President and Assistant Secretary
				
	GUARANTORS:		RATTLER MIDSTREAM LP
				
				
			By:	Rattler Midstream GP LLC, its General Partner
				
			By:	/s/ Teresa L. Dick
			Name:	Teresa L. Dick
			Title:	Chief Financial Officer, Executive Vice President and Assistant Secretary
				
			TALL CITY TOWERS LLC
				
				
			By:	/s/ Teresa L. Dick
			Name:	Teresa L. Dick
			Title:	Chief Financial Officer, Executive Vice President and Assistant Secretary
				
			RATTLER OMOG LLC
				
				
			By:	Rattler Midstream Operating LLC, its sole member
				
			By:	/s/ Teresa L. Dick
			Name:	Teresa L. Dick
			Title:	Chief Financial Officer, Executive Vice President and Assistant Secretary
				
				

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
			RATTLER AJAX PROCESSING LLC
				
			By:	Rattler Midstream Operating LLC, its sole member
				
			By:	/s/ Teresa L. Dick
			Name:	Teresa L. Dick
			Title:	Chief Financial Officer, Executive Vice President and Assistant Secretary

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	ADMINISTRATIVE AGENT,		WELLS FARGO BANK, NATIONAL
	ISSUING BANK AND LENDER:		ASSOCATION, as Administrative Agent, Issuing
			Bank and as a Lender
				
			By:	/s/ Andrew Ostrov
			Name:	Andrew Ostrov
			Title:	Director

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		BANK OF AMERICA, N.A.
			
			
			By:	/s/ Ronald E. McKaig
			Name:	Ronald E. McKaig
			Title:	Managing Director

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		CREDIT SUISSE AG, CAYMAN ISLANDS
			BRANCH
			
			By:	/s/ Nupur Kumar
			Name:	Nupur Kumar
			Title:	Authorized Signatory
				
			By:	/s/ Andrew Griffin
			Name:	Andrew Griffin
			Title:	Authorized Signatory
				

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		JPMORGAN CHASE BANK, N.A.
			
			
			By:	/s/ Michael A. Kamauf
			Name:	Michael A. Kamauf
			Title:	Authorized Officer

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		CITIBANK, N.A.
			
			
			By:	/s/ Jeff Ard
			Name:	Jeff Ard
			Title:	Vice President

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		PNC BANK, NATIONAL ASSOCIATION
			
			
			By:	/s/ John Engel
			Name:	John Engel
			Title:	Vice President

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		BARCLAYS BANK PLC
			
			
			By:	/s/ Sydney G. Dennis
			Name:	Sydney G. Dennis
			Title:	Director

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		CAPITAL ONE, NATIONAL ASSOCIATION
			
			
			By:	/s/ Christopher Kuna
			Name:	Christopher Kuna
			Title:	Senior Director

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		TRUIST BANK, successor by merger to SunTrust
			Bank, as a Lender
			
			By:	/s/ Samantha Sanford
			Name:	Samantha Sanford
			Title:	Vice President

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		THE BANK OF NOVA SCOTIA, HOUSTON
			BRANCH
			
			By:	/s/ Scott Nickel
			Name:	Scott Nickel
			Title:	Director

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		U.S. BANK NATIONAL ASSOCIATION
			
			
			By:	/s/ Bruce E. Hernandez
			Name:	Bruce E. Hernandez
			Title:	Senior Vice President

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENT

        

												
	LENDERS:		GOLDMAN SACHS BANK USA
			
			
			By:	/s/ Mahesh Mohan
			Name:	Mahesh Mohan
			Title:	Authorized Signatory

SIGNATURE PAGE
SECOND AMENDMENT TO CREDIT AGREEMENTExhibit
10.1

 

 

 

Stock
Purchase Agreement

 

By
and Among

 

NutraLife
Biosciences, Inc.;

 

Lord
Global Corporation

 

And

 

27
Health, Inc.

 

Dated
as of November 2, 2020

 

 

 

    	 

     

    

 

TABLE
OF CONTENTS

 

	Article
    I.	DEFINITIONS	1
	 	 	 	
	 	Section
    1.01	Definitions.	1
	 	Section
    1.02	Interpretive
    Provisions.	3
	 	 	 	
	Article
    II.	PURCHASE
    AND SALE	3
	 	 	 	
	 	Section
    2.01	Purchase
    and Sale.	3
	 	Section
    2.02	Deliverables
    at Closing.	3
	 	Section
    2.03	Closing.	3
	 	Section
    2.04	Adjustments
    to Shares.	3
	 	 	 	
	Article
    III.	REPRESENTATIONS
    AND WARRANTIES OF COMPANY PARTIES	5
	 	 	 	
	 	Section
    3.01	Authorization
    of Transactions.	5
	 	Section
    3.02	Governmental
    Approvals; Non-contravention.	6
	 	Section
    3.03	Investment
    Representations.	6
	 	Section
    3.04	Brokers.	8
	 	 	 	
	Article
    IV.	REPRESENTATIONS
    AND WARRANTIES OF BUYER	9
	 	 	 	
	 	Section
    4.01	Authorization
    of Transactions.	9
	 	Section
    4.02	Governmental
    Approvals; Non-contravention.	9
	 	Section
    4.03	Investment
    Representations.	9
	 	Section
    4.04	Brokers.	11
	 	 	 	
	Article
    V.	INDEMNIFICATION	11
	 	 	 	
	 	Section
    5.01	General
    Indemnification.	11
	 	Section
    5.02	Procedures
    for Indemnification.	12
	 	Section
    5.03	Payment.	12
	 	Section
    5.04	Effect
    of Knowledge on Indemnification.	12
	 	 	 	
	Article
    VI.	MISCELLANEOUS	12
	 	 	 	
	 	Section
    6.01	Notices.	12
	 	Section
    6.02	Entire
    Agreement.	13
	 	Section
    6.03	Survival.	13
	 	Section
    6.04	Binding
    Effect; Assignment.	13
	 	Section
    6.05	Amendment.	14
	 	Section
    6.06	Further
    Assurances.	14
	 	Section
    6.07	No
    Waiver.	14
	 	Section
    6.08	Headings.	14
	 	Section
    6.09	Governing
    Law.	14
	 	Section
    6.10	Specific
    Performance.	14
	 	Section
    6.11	Enforcement
    of the Agreement; Jurisdiction; No Jury Trial.	14
	 	Section
    6.12	Arbitration.	15
	 	Section
    6.13	Attorneys’
    Fees.	15
	 	Section
    6.14	Severability;
    Expenses.	15
	 	Section
    6.15	Parties
    in Interest.	15
	 	Section
    6.16	Execution
    in Counterparts, Electronic Transmission.	15

 

	Exhibit
    A	Certificate
    of Designations, Preferences and Rights of Series X Convertible Preferred Stock

 

    	i

     

    

 

STOCK
PURCHASE AGREEMENT

 

This
Stock Purchase Agreement (together with all exhibits and schedules hereto, this “Agreement”) is entered into as of
November 2, 2020 (the “Closing Date”), by and among Lord Global Corporation, a Nevada corporation (the “Company”),
27 Health, Inc., a wholly-owned subsidiary of the Company (“27 Health”) and NutraLife Biosciences, Inc., a Florida
corporation (“Buyer”). The Company, 27 Health and Buyer may be collectively referred to herein as the “Parties”
and individually as a “Party.” The Company and 27 may be referred to herein individually as a “Company Party”
and collectively as the “Company Parties”.

 

WHEREAS,
the Company desires to issue and sell to the Buyer certain shares of the Company’s Series X Convertible Preferred Stock,
par value $0.001 (the “Series X Preferred Stock”), each share of which is convertible into shares of the Company’s
common stock, par value $0.001 per share (the “Common Stock”), and Buyer desires to buy certain shares of the Series
X Preferred Stock, as set forth herein; and

 

WHEREAS,
the Buyer acknowledges and understands that the shares of Series X Preferred Stock issuable to the Buyer pursuant to this Agreement
are subject to the Certificate of Designations, Preferences and Rights of Series X Convertible Preferred Stock filed with the
State of Nevada on November 2, 2020, a copy of which is attached hereto as Exhibit A (the “Series X Certificate of Designations”),
which contains therein a beneficial ownership limitation or blocker provision that precludes any Holder from exercising the conversion
rights of the Series X Preferred Stock if, as a result of such conversion, the Holder and its affiliates would result in beneficial
ownership of more than 4.9% of the Company’s then-outstanding shares of Common Stock;

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

Article
I. DEFINITIONS

 

Section
1.01 Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms, as used herein, have
the following meanings:

 

	 	(a)	“Affiliate”
    means, with respect to a specified Person, any other Person that directly or indirectly Controls, is Controlled by or is under
    common Control with, the specified Person.
	 	 	 
	 	(b)	“Business
    Day” means any day except Saturday, Sunday and any legal holiday or a day on which banking institutions in Nevada generally
    are authorized or required by Law or other governmental actions to close.
	 	 	 
	 	(c)	“Contract”
    means any contract, commitment, understanding or agreement (whether oral or written).
	 	 	 
	 	(d)	“Control”
    means (a) the possession, directly or indirectly, of the power to vote 10% or more of the securities or other equity interests
    of a Person having ordinary voting power, (b) the possession, directly or indirectly, of the power to direct or cause the
    direction of the management and policies of a Person, by contract or otherwise, or (c) being a director, officer, executor,
    trustee or fiduciary (or their equivalents) of a Person or a Person that controls such Person.

 

    	1

     

    

 

	 	(e)	“Governmental
    Entity” means any federal, state, municipal, local or foreign government and any court, tribunal, arbitral body, administrative
    agency, department, subdivision, entity, commission or other governmental, government appointed, quasi-governmental or regulatory
    authority, reporting entity or agency, domestic, foreign or supranational.
	 	 	 
	 	(f)	“Law”
    means any applicable foreign, federal, state or local law (including common law), statute, treaty, rule, directive, regulation,
    ordinances and similar provisions having the force or effect of law or an Order of any Governmental Entity.
	 	 	 
	 	(g)	 “Liabilities”
    means liabilities, obligations or responsibilities of any nature whatsoever, whether direct or indirect, matured or un-matured,
    fixed or unfixed, known or unknown, asserted or un asserted, choate or inchoate, liquidated or unliquidated, secured or unsecured,
    absolute, contingent or otherwise, including any direct or indirect indebtedness, guaranty, endorsement, claim, loss, damage,
    deficiency, cost or expense.
	 	 	 
	 	(h)	“Lien”
    means, with respect to any property or asset, any lien, security interest, mortgage, pledge, charge, claim, lease, agreement,
    right of first refusal, option, limitation on transfer or use or assignment or licensing, restrictive easement, charge or
    any other restriction of any kind, and any conditional sale or voting agreement or proxy, and including any restriction on
    the ownership, use, voting, transfer, possession, receipt of income or other exercise of any attributes of ownership, in respect
    of such property or asset, and any agreement to give any of the foregoing.
	 	 	 
	 	(i)	“Losses”
    means any losses, damages, deficiencies, Liabilities, assessments, fines, penalties, judgments, actions, claims, costs, disbursements,
    fees, expenses or settlements of any kind or nature, including legal, accounting and other professional fees and expenses.
	 	 	 
	 	(j)	“Order”
    means any judgment, writ, decree, determination, award, compliance agreement, settlement agreement, injunction, ruling, charge,
    judicial or administrative order, determination or other restriction of any Governmental Entity or arbitrator.
	 	 	 
	 	(k)	“Person”
    means a natural person, a corporation, a limited liability company, a partnership, an association, a trust or any other entity
    or organization, including a government or political subdivision or any agency or instrumentality thereof.
	 	 	 
	 	(l)	“Securities
    Act” means the United States Securities Act of 1933, as amended, and the rules and regulation promulgated thereunder.
	 	 	 
	 	(m)	“Transactions”
    means the purchase and sale of the Series X Preferred Stock and the other transactions contemplated under the Transaction
    Documents.
	 	 	 
	 	(n)	“Transaction
    Documents” means this Agreement and any other agreement, document, certificate or writing delivered or to be delivered
    in connection with this Agreement and any other document related to the Transactions related to the forgoing, including, without
    limitations, those delivered at the Closing.

 

    	2

     

    

 

Section
1.02Interpretive Provisions. Unless the express context otherwise requires, the words “hereof,” “herein,”
and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole
and not to any particular provision of this Agreement; terms defined in the singular shall have a comparable meaning when used
in the plural, and vice versa; the terms “Dollars” and “$” mean United States Dollars, unless otherwise
specified herein; references herein to a specific Section, Subsection, Recital or Exhibit shall refer, respectively, to Sections,
Subsections, Recitals or Exhibits of this Agreement; wherever the word “include,” “includes,” or “including”
is used in this Agreement, it shall be deemed to be followed by the words “without limitation”; references herein
to any gender shall include each other gender; references herein to any Person shall include such Person’s heirs, executors,
personal representatives, administrators, successors and assigns; provided, however, that nothing contained in this Section 1.02
is intended to authorize any assignment or transfer not otherwise permitted by this Agreement; references herein to a Person in
a particular capacity or capacities shall exclude such Person in any other capacity; references herein to any Contract or agreement
(including this Agreement) mean such Contract or agreement as amended, supplemented or modified from time to time in accordance
with the terms thereof; with respect to the determination of any period of time, the word “from” means “from
and including” and the words “to” and “until” each means “to but excluding”; references
herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or superseded
in whole or in part, and in effect from time to time; and references herein to any Law shall be deemed also to refer to all rules
and regulations promulgated thereunder.

 

Article
II. PURCHASE AND SALE

 

Section
2.01 Purchase and Sale. Subject to the terms and conditions of this Agreement and as set forth below, at the Closing (as
defined below) the Company shall issue and sell to Buyer two hundred and fifty (250) shares of the Company’s Series X Convertible
Preferred Stock (“Series X Preferred Stock”), each share of which is initially convertible into one thousand (1,000)
shares of the Company’s Common Stock, subject to customary adjustments (subject to the provisions of Section 2.04, the “Shares”)
in return for the issuance by the Buyer to 27 Health of 12,500,000 shares of common stock, par value $0.0001 per share, of the
Buyer (the “NutraLife Shares”).

 

Section
2.02 Deliverables at Closing. At the Closing (as defined below):

 

	 	(a)	the
    Buyer shall issue to 27 Health the NutraLife Shares via book entry in the books and records of NutraLife and shall provide
    reasonable evidence thereof to the Company; and
	 	 	 
	 	(b)	the
    Company shall issue to Buyer the Shares via book entry in the books and records of the Company and shall provide reasonable
    evidence thereof to the Buyer.

 

Section
2.03 Closing. On the terms set forth herein, the closing of the Transactions (the “Closing”) shall take place
by conference call and electronic communication (i.e., emails/pdf) or facsimile of closing documents, on the Closing Date and
effective as of 11:59 p.m. Eastern time on the Closing Date.

 

Section
2.04 Adjustments to Shares.

 

	 	(a)	In
    the event that, on the first Business Day following the 180-day anniversary of the Closing Date (the “First Adjustment
    Date”), the Share Price (as defined below) is less than $4.00 (subject to adjustment as set forth in the “Base
    Share Value”), the Company shall issue to NutraLife, for no additional consideration payable by NutraLife, a number
    of shares of Common Stock equal to (1) (i) $1,000,000, divided by (ii) the Share Price as of the First Adjustment Date, rounded
    to the nearest whole share, minus (2) 250,000 (the “First Adjustment Shares”). By way of example and not limitation,
    in the event that as of the First Adjustment Date the Share Price is $3.00, the Company shall issue to NutraLife 83,333 additional
    shares of Common Stock ($1,000,000 divided by $3.00, less 250,000).

 

    	3

     

    

 

	 	(b)	In
    the event that, on the first Business Day following the one-year anniversary of the Closing Date (the “Second Adjustment
    Date”), the Share Price is less than the Base Share Value, the Company shall issue to NutraLife, for no additional consideration
    payable by NutraLife, an additional number of shares of Common Stock equal to (1) (i) $1,000,000, divided by (ii) the Share
    Price as of the Second Adjustment Date, rounded to the nearest whole share, minus (2) 250,000, minus (3) any number of First
    Adjustment Shares issued to NutraLife pursuant to Section 2.04(a) (the “Second Adjustment Shares”). By way of
    example and not limitation, in the event that as of the Second Adjustment Date the Share Price is $2.00 and the Company had
    issued to NutraLife 83,333 First Adjustment Shares pursuant to Section 2.04(a), the Company shall issue to NutraLife 166,667
    additional shares of Common Stock ($1,000,000 divided by $2.00, less 250,000, less 83,333).
	 	 	 
	 	(c)	The
    term “Shares” as used herein refers to shares of Company’s Common Stock, with respect to Share Price, and
    shares of Series X Preferred Stock, with respect to the shares issuable to Buyer under this Agreement, and shall include the
    First Adjustment Shares and the Second Adjustment Shares if and when issued.
	 	 	 
	 	(d)	For
    purposes herein, the term “Share Price” shall mean the average VWAP of the Company’s Common Stock for the
    ten (10) Trading Day period (as defined below) prior to any date for determination of the Share Price. For purposes herein,
    “VWAP” means, for shares of the Company’s Common Stock as of any date, the first of the following which
    shall apply:

 

	 	 	(i)	the
    dollar volume-weighted average price for such shares of Common Stock on the OTC Markets or a United States national securities
    exchange which is the principal market on which such shares of Common Stock are then traded (as applicable, the “Trading
    Market”) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported
    by Bloomberg L.P. through its “HP” function (set to weighted average) or, if the foregoing does not apply, the
    dollar volume-weighted average price of such shares of Common Stock in the over-the-counter market on the electronic bulletin
    board for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time,
    as reported by Bloomberg L.P.;
	 	 	 	 
	 	 	(ii)	if
    no dollar volume-weighted average price is reported for such shares of Common Stock by Bloomberg L.P. for such hours as set
    forth in Section 2.04(d)(i), the average of the highest closing bid price and the lowest closing ask price of any of the market
    makers for such shares of Common Stock as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink
    Sheets LLC); and
	 	 	 	 
	 	 	(iii)	if
    the VWAP cannot be calculated for such shares of Common Stock on such date on bases as set forth in Section 2.04(d)(i) or
    Section 2.04(d)(ii), the VWAP of such shares of Common Stock on such date shall be the fair market value of such shares of
    Common Stock as mutually determined in good faith by the Board of Directors of the Company and the Board of Directors of the
    Buyer after taking into consideration factors they may each deem appropriate, and provided that if the Company and the Board
    of Directors of the Buyer cannot so agree then such dispute shall be settled in accordance with the provisions for resolutions
    of disputes as set forth in the Agreement.

 

    	4

     

    

 

	 	(e)	All
    such determinations of the VWAP as set forth in Section 2.04(d)(i) or Section 2.04(d)(ii) shall be appropriately adjusted
    for any stock dividend, stock split, stock combination, recapitalization or other similar transaction during such period.
	 	 	 
	 	(f)	For
    purposes herein, “Trading Day” means any day on which the Common Stock (or any replacement security pursuant to
    Section 2.04(g)) is traded on the Trading Market or is otherwise reported on “pink sheets” by OTC Markets Group
    Inc. (formerly Pink Sheets LLC) or a similar organization or agency succeeding to its functions of reporting prices.
	 	 	 
	 	(g)	If,
    at any time prior to First Adjustment Date or the Second Adjustment Date, there shall be any merger, consolidation, or an
    exchange of shares, recapitalization or reorganization pursuant to a merger or consolidation, or other similar event, as a
    result of which shares of Common Stock shall be changed into the same or a different number of shares of another class or
    classes of stock or securities of the Company or another entity, or in case of any sale or conveyance of all or substantially
    all of the assets or more than 50% of the total outstanding shares of the Company other than in connection with a plan of
    complete liquidation of the Company, then the Buyer shall thereafter have the right to receive at the First Adjustment Date
    or the or the Second Adjustment Date, as applicable, upon the basis and upon the terms and conditions specified herein and
    in lieu of the shares of Common Stock pursuant to Section 2.04(a) and Section 2.04(b), such replacement stock, securities
    or assets, with equitable adjustments being made thereto with respect to the Share Price, as determined by the Company and
    the Buyer.
	 	 	 
	 	(h)	The
    Base Share Value, as the same may have already been adjusted, shall be subject to equitable adjustments for stock splits,
    stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary
    of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events that occur
    on or after the Closing Date. By way of example and not limitation, in the event of forward split of the Common Stock following
    the Closing Date in which each share of Common Stock is converted into two shares of Common Stock, the Base Share Value shall
    be reduced by 50%, and in the event of a reverse split of the Common Stock following the Closing Date in which each two shares
    of Common Stock are converted into one share of Common Stock, the Base Share Value shall be increased by 100%.

 

Article
III. REPRESENTATIONS AND WARRANTIES OF COMPANY PARTIES

 

The
Company Parties, jointly and severally, represent and warrant to Buyer that the following representations and warranties contained
in this Article III are true and correct as of the Closing Date, as of the First Adjustment Date and as of the Second Adjustment
Date:

 

Section
3.01 Authorization of Transactions. The Company is a corporation duly authorized and in good standing in the State of Nevada
and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform
its obligations hereunder and thereunder. 27 Health is a corporation duly authorized and in good standing in the State of Delaware
and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform
its obligations hereunder and thereunder. The execution, delivery and performance by each Company Party of the applicable Transaction
Documents and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part of
each Company Party. The Transaction Documents to which each Company Party is a party have been duly and validly executed and delivered
by such Company Party. Each Transaction Document to which such Company Party is a party constitutes the valid and legally binding
obligation of such Company Party, enforceable against such Company Party in accordance with its terms and conditions, except to
the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other Laws affecting the enforcement of
creditors’ rights or by the principles governing the availability of equitable remedies.

 

    	5

     

    

 

Section
3.02 Governmental Approvals; Non-contravention.

 

	 	(a)	No
    consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
    or Person is necessary for the execution, delivery or performance by either Company Party of this Agreement or any other Transaction
    Document to which such Company Party is a party.
	 	 	 
	 	(b)	The
    execution, delivery and performance by each Company Party of the Transaction Documents to which either Company Party is a
    party, and the consummation by the Company Parties of the Transactions, do not (i) violate or conflict with any Law or Order
    to which either Company Party or any of the Shares may be subject, (ii) constitute a violation or breach of, be in conflict
    with, constitute or create (with or without due notice or lapse of time or both) a default (or give rise to any right of termination,
    modification, cancellation or acceleration) of any obligation under any Contract to which either Company Party is a party
    or to which either Company Party or any of the Shares are subject or by which the either Company Party’s properties,
    assets or rights are bound or (iii) result in the creation or imposition of any Lien upon any of the rights, properties or
    assets of either Company Party or on any of the Shares.

 

Section
3.03 Investment Representations.

 

	 	(a)	Each
    Company Party understands and agrees that the consummation of this Agreement including the delivery of the NutraLife Shares
    to 27 Health as contemplated hereby constitutes the offer and sale of securities under the Securities Act and applicable state
    statutes and that the NutraLife Shares are being acquired for the Company’s and 27 Health’s own account and not
    with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from
    registration under the Securities Act.
	 	 	 
	 	(b)	Each
    Company Party is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D under the Securities
    Act (an “Accredited Investor”).
	 	 	 
	 	(c)	Each
    Company Party understands that the NutraLife Shares are being offered and sold to the Company and 27 Health in reliance upon
    specific exemptions from the registration requirements of United States federal and state securities Laws and that Buyer is
    relying upon the truth and accuracy of, and each Company Party’s compliance with, the representations, warranties, agreements,
    acknowledgments and understandings of the Company Parties set forth herein in order to determine the availability of such
    exemptions and the eligibility of the Company and 27 Health to acquire the NutraLife Shares.

 

    	6

     

    

 

	 	(d)	Each
    Company Party and their respective advisors, if any, have been furnished with all materials relating to the business, finances
    and operations of Buyer and materials relating to the offer and sale of the NutraLife Shares which have been requested by
    either Company Party or their respective advisors. The Company Parties and their respective advisors, if any, have been afforded
    the opportunity to ask questions of the Buyer. The Company Parties understand that their investment in the NutraLife Shares
    involves a significant degree of risk.
	 	 	 
	 	(e)	At
    no time was either Company Party presented with or solicited by any leaflet, newspaper or magazine article, radio or television
    advertisement, or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise
    than in connection and concurrently with such communicated offer. Neither Company Party is purchasing the NutraLife Shares
    acquired by 27 Health hereunder as a result of any “general solicitation” or “general advertising,”
    as such terms are defined in Regulation D under the Securities Act, which includes, but is not limited to, any advertisement,
    article, notice or other communication regarding the NutraLife Shares acquired hereunder published in any newspaper, magazine
    or similar media or on the internet or broadcast over television, radio or the internet or presented at any seminar or any
    other general solicitation or general advertisement.
	 	 	 
	 	(f)	The
    Company Parties are acquiring the NutraLife Shares for their own account as principal, not as a nominee or agent, for investment
    purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no
    other person has a direct or indirect beneficial interest in the NutraLife Shares. Further, neither Company Party has any
    Contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or
    to any third person, with respect to the NutraLife Shares.
	 	 	 
	 	(g)	Each
    Company Party understands that (i) the sale or re-sale of the NutraLife Shares has not been and is not being registered under
    the Securities Act or any applicable state securities laws, and the NutraLife Shares may not be transferred unless (1) the
    NutraLife Shares are sold pursuant to an effective registration statement under the Securities Act, (2) the Company Parties
    shall have delivered to Buyer, at the cost of the Company, an opinion of counsel that shall be in form, substance and scope
    customary for opinions of counsel in comparable transactions to the effect that the NutraLife Shares to be sold or transferred
    may be sold or transferred pursuant to an exemption from such registration, which opinion shall be accepted by Buyer, (3)
    the NutraLife Shares are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the Securities
    Act (or a successor rule) (“Rule 144”)) of the Company who agrees to sell or otherwise transfer the NutraLife
    Shares only in accordance with this Section and who is an Accredited Investor, (4) the NutraLife Shares are sold pursuant
    to Rule 144, (5) the NutraLife Shares are sold pursuant to Regulation S under the Securities Act (or a successor rule) (“Regulation
    S”), or (6) the NutraLife Shares are sold pursuant to the exemption from registration afforded under Section 4(a)(1)
    or Section 4(a)(7) of the Securities Act, and the Company shall have delivered to Buyer, at the cost of the Company, an opinion
    of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate transactions, which opinion
    shall be accepted by Buyer; (ii) any sale of such NutraLife Shares made in reliance on Rule 144 may be made only in accordance
    with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such NutraLife Shares under circumstances
    in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined
    in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations
    of the Securities and Exchange Commission thereunder; and (iii) neither Buyer nor any other person is under any obligation
    to register such NutraLife Shares under the Securities Act or any state securities laws or to comply with the terms and conditions
    of any exemption thereunder (in each case).

 

    	7

     

    

 

	 	(h)	Each
    Company Party understands that no public market now exists for the NutraLife Shares, and that Buyer has made no assurances
    that a public market will ever exist for the NutraLife Shares.
	 	 	 
	 	(i)	Each
    Company Party, either alone or together with its respective representatives, has such knowledge, sophistication and experience
    in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in
    the NutraLife Shares, and has so evaluated the merits and risks of such investment. Each Company Party is able to bear the
    economic risk of an investment in the NutraLife Shares and, at the present time, is able to afford a complete loss of such
    investment.
	 	 	 
	 	(j)	Each
    Company Party understands that no United States federal or state agency or any other governmental or state agency has passed
    on or made recommendations or endorsement of the NutraLife Shares or the suitability of the investment in the NutraLife Shares
    nor have such authorities passed upon or endorsed the merits of the transactions set forth herein.
	 	 	 
	 	(k)	Any
    legend required by the securities laws of any state to the extent such laws are applicable to the NutraLife Shares represented
    by the certificate so legended shall be included on any certificates representing the NutraLife Shares. Each Company Party
    also understands that the NutraLife Shares may bear the following or a substantially similar legend:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED
OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED,
PLEDGED, OR HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT
SET FORTH HEREIN.

 

Section
3.04 Brokers. Neither Company Party has engaged, or caused to be incurred any Liability or obligation to, any investment
banker, finder, broker or sales agent or any other Person in connection with the origin, negotiation, execution, delivery or performance
of the Transaction Documents to which it is a party, or the Transactions.

 

    	8

     

    

 

Article
IV. REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer
represents and warrants to the Company Parties that the following statements contained in this Article IV are true and correct
as of the Closing Date, as of the First Adjustment Date and as of the Second Adjustment Date:

 

Section
4.01 Authorization of Transactions. Buyer is corporation, duly authorized and in good standing in the State of Florida
and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to perform
its obligations hereunder and thereunder. The execution, delivery and performance by Buyer of the applicable Transaction Documents
and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part of Buyer. The
Transaction Documents to which Buyer is a party have been duly and validly executed and delivered by Buyer. Each Transaction Document
to which Buyer is a party constitutes the valid and legally binding obligation of Buyer, enforceable against Buyer in accordance
with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or
other Laws affecting the enforcement of creditors’ rights or by the principles governing the availability of equitable remedies.

 

Section
4.02 Governmental Approvals; Non-contravention.

 

	 	(a)	No
    consent, Order, action or non-action of, or filing, notification, declaration or registration with, any Governmental Entity
    is necessary for the execution, delivery or performance by Buyer of this Agreement or any other Transaction Document to which
    Buyer is a party.
	 	 	 
	 	(b)	The
    execution, delivery and performance by Buyer of the Transaction Documents to which Buyer is a party, and the consummation
    by Buyer of the Transactions, do not (i) violate any Laws or Orders to which Buyer is subject or (ii) violate, breach or conflict
    with any provision of Buyer’s organizational documents.

 

Section
4.03 Investment Representations.

 

	 	(a)	Buyer
    understands and agrees that the consummation of this Agreement including the delivery of the Shares to Buyer as contemplated
    hereby constitutes the offer and sale of securities under the Securities Act and applicable state statutes and that the Shares
    are being acquired for Buyer’s own account and not with a present view towards the public sale or distribution thereof,
    except pursuant to sales registered or exempted from registration under the Securities Act.
	 	 	 
	 	(b)	Buyer
    is an Accredited Investor.
	 	 	 
	 	(c)	Buyer
    understands that the Shares are being offered and sold to Buyer in reliance upon specific exemptions from the registration
    requirements of United States federal and state securities Laws and that the Company is relying upon the truth and accuracy
    of, and Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of
    Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of Buyer to acquire the
    Shares.
	 	 	 
	 	(d)	Buyer
    and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the
    Company and materials relating to the offer and sale of the Shares which have been requested by Buyer or its advisors. Buyer
    and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Buyer understands that its investment
    in the Shares involves a significant degree of risk.

 

    	9

     

    

 

	 	(e)	At
    no time was Buyer presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement,
    or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection
    and concurrently with such communicated offer. Buyer is not purchasing the Shares acquired by Buyer hereunder as a result
    of any “general solicitation” or “general advertising,” as such terms are defined in Regulation D
    under the Securities Act, which includes, but is not limited to, any advertisement, article, notice or other communication
    regarding the Shares acquired by Buyer hereunder published in any newspaper, magazine or similar media or on the internet
    or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general
    advertisement.
	 	 	 
	 	(f)	Buyer
    is acquiring the Shares for its own account as principal, not as a nominee or agent, for investment purposes only, and not
    with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no other person has a direct
    or indirect beneficial interest in the Shares. Further, Buyer does not have any Contract, undertaking, agreement or arrangement
    with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Shares.
	 	 	 
	 	(g)	Buyer
    understands that (i) the sale or re-sale of the Shares has not been and is not being registered under the Securities Act or
    any applicable state securities laws, and the Shares may not be transferred unless (1) the Shares are sold pursuant to an
    effective registration statement under the Securities Act, (2) Buyer shall have delivered to the Company, at the cost of Buyer,
    an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions
    to the effect that the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration,
    which opinion shall be accepted by the Company, (3) the Shares are sold or transferred to an “affiliate” (as defined
    in Rule 144) of Buyer who agrees to sell or otherwise transfer the Shares only in accordance with this Section and who is
    an Accredited Investor, (4) the Shares are sold pursuant to Rule 144, (5) the Shares are sold pursuant to Regulation S, or
    (6) the Shares are sold pursuant to the exemption from registration afforded under Section 4(a)(1) or Section 4(a)(7) of the
    Securities Act, and Buyer shall have delivered to the Company, at the cost of Buyer, an opinion of counsel that shall be in
    form, substance and scope customary for opinions of counsel in corporate transactions, which opinion shall be accepted by
    the Company; (ii) any sale of such Shares made in reliance on Rule 144 may be made only in accordance with the terms of said
    Rule and further, if said Rule is not applicable, any re-sale of such Shares under circumstances in which the seller (or the
    person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may
    require compliance with some other exemption under the Securities Act or the rules and regulations of the Securities and Exchange
    Commission thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Shares
    under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder
    (in each case).
	 	 	 
	 	(h)	Buyer
    understands that no public market now exists for the Shares, and that the Company has made no assurances that a public market
    will ever exist for the Shares.
	 	 	 
	 	(i)	Buyer,
    either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
    matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated
    the merits and risks of such investment. Buyer is able to bear the economic risk of an investment in the Shares and, at the
    present time, is able to afford a complete loss of such investment.

 

    	10

     

    

 

	 	(j)	Buyer
    understands that no United States federal or state agency or any other governmental or state agency has passed on or made
    recommendations or endorsement of the Shares or the suitability of the investment in the Shares nor have such authorities
    passed upon or endorsed the merits of the transactions set forth herein.
	 	 	 
	 	(k)	Any
    legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the
    certificate so legended shall be included on any certificates representing the Shares. Buyer also understands that the Shares
    may bear the following or a substantially similar legend:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED
OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED,
PLEDGED, OR HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT
SET FORTH HEREIN.

 

Section
4.04 Brokers. Buyer has not engaged any investment banker, finder, broker or sales agent or any other Person in connection
with the origin, negotiation, execution, delivery or performance of any Transaction Document to which it is a party, or the Transactions.

 

Article
V. INDEMNIFICATION

 

Section
5.01 General Indemnification.

 

	 	(a)	Buyer
    agrees to indemnify, defend and hold harmless the Company Parties and their respective Affiliates and each of their respective
    directors, officers, managers, partners, employees, agents, equity holders, successors and assigns (each, a “Company
    Indemnified Party”), from and against any and all Losses incurred or suffered by any Company Indemnified Party arising
    out of, based upon or resulting from any breach of any representation or warranty of Buyer herein or breach by Buyer of, or
    any failure of Buyer to perform, any of the covenants, agreements or obligations of Buyer contained in or made pursuant to
    this Agreement of the other Transaction Documents by Buyer.
	 	 	 
	 	(b)	The
    Company parties, jointly and severally, agree to indemnify, defend and hold harmless the Buyer and its Affiliates and each
    of their respective directors, officers, managers, partners, employees, agents, equity holders, successors and assigns (each,
    a “NutraLife Indemnified Party”), from and against any and all Losses incurred or suffered by any NutraLife Indemnified
    Party arising out of, based upon or resulting from any breach of any representation or warranty of any Company Party herein
    or breach by any Company Party of, or any failure of any Company Party to perform, any of the covenants, agreements or obligations
    either Company Party contained in or made pursuant to this Agreement of the other Transaction Documents by either Company
    Party or both Company Parties.
	 	 	 
	 	(c)	The
    person or entity claiming any indemnification hereunder is referred to herein as the “Indemnified Party” and the
    entity from which indemnification hereunder is sought is referred to herein as the “Indemnifying Party”.

 

    	11

     

    

 

Section
5.02 Procedures for Indemnification. In the event that an Indemnified Party shall incur or suffer any Losses in respect
of which indemnification may be sought under this Article V against the Indemnifying Party, the Indemnified Party shall assert
a claim for indemnification by providing a written notice (the “Notice of Loss”) to the Indemnifying Party stating
the nature and basis of such indemnification. The Notice of Loss shall be provided to the Indemnifying Party as soon as practicable
after the Indemnified Party becomes aware that it has incurred or suffered a Loss.

 

Section
5.03 Payment. Upon a determination of liability under this Article V the Indemnifying Party shall pay or cause to be paid
to the Indemnified Party the amount so determined within five (5) Business Days after the date of such determination. If there
should be a dispute as to the amount or manner of determination of any indemnity obligation owed under this Agreement or the other
Transaction Documents, the Indemnifying Party shall nevertheless pay when due such portion, if any, of the obligation that is
not subject to dispute. Upon the payment in full of any amounts due under this Article V with respect to any claim, the Indemnifying
Party shall be subrogated to the rights of the Indemnified Party against any Person with respect to the subject matter of such
claim.

 

Section
5.04 Effect of Knowledge on Indemnification. The right to indemnification, reimbursement or other remedy based upon any
representations, warranties, covenants and obligations set forth in this Agreement or the other Transaction Documents shall not
be affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time,
whether before or after the execution and delivery of this Agreement or the other Transaction Documents, with respect to the accuracy
or inaccuracy of or compliance with any such representation, warranty, covenant or obligation. The waiver of any condition based
upon the accuracy of any representation or warranty, or on the performance of or compliance with any covenant or obligation, shall
not affect the right to indemnification, reimbursement or other remedy based upon such representations, warranties, covenants
or obligations.

 

Article
VI. MISCELLANEOUS

 

Section
6.01 Notices. All notices under this Agreement shall be in writing. Notices may be served by certified or registered mail,
postage paid with return receipt requested; by private courier, prepaid; by other reliable form of electronic communication; or
personally. Mailed notices shall be deemed delivered five (5) days after mailing, properly addressed. Couriered notices shall
be deemed delivered on the date that the courier warrants that delivery will occur. Electronic communication notices shall be
deemed delivered when receipt is either confirmed by confirming transmission equipment or acknowledged by the addressee or its
office. Personal delivery shall be effective when accomplished. Any Party may change its address by giving notice, in writing,
stating its new address, to the other Parties. Subject to the forgoing, notices shall be sent as follows:

 

If
to NutraLife:

 

NutraLife
Biosciences, Inc.

Attn:
Edgar Ward

6601
Lyons Road, Suite L-6

Coconut
Creek, FL 33073

Email:
edgar@nutralifebiosciences.com

 

    	12

     

    

 

With
a copy, which shall not constitute notice, to:

 

Anthony
L.G., PLLC

Attn:
John Cacomanolis

625
N. Flagler Drive, Suite 600

West
Palm Beach, FL 33401

Email:
JCacomanolis@anthonypllc.com

 

If
to any Company Party, to:

 

Lord
Global Corporation

Attn:
Joseph Frontiere

318
N Carson St.

Suite
208

Carson
City, NV 89701

Email:
jfrontiere@gmail.com

 

With
a copy, which shall not constitute notice, to:

 

The
Lonergan Law Firm, PLLC

Attn:
Lawrence R. Lonergan, Esq.

96
Park Street

Montclair,
NJ 07042

Email:
llonergan@wlesq.com

 

Section
6.02 Entire Agreement. This Agreement sets forth all the promises, covenants, agreements, conditions and understandings
between the Parties, and supersedes all prior and contemporaneous agreements, understandings, inducements or conditions, expressed
or implied, oral or written, except as herein or therein contained.

 

Section
6.03 Survival. The provisions of Article V and Article VI of this Agreement, and such additional provisions as required
to give effect thereto, shall survive any termination or expiration hereof, and provided that no expiration or termination of
this Agreement shall excuse a Party for any liability for obligations arising prior to such expiration or termination.

 

Section
6.04 Binding Effect; Assignment. This Agreement shall be binding upon the Parties, their heirs, administrators, successors
and assigns. Except as otherwise provided in this Agreement, no Party may otherwise assign or transfer its interests herein, or
delegate its duties hereunder, without the written consent of the other Parties. Any assignment or delegation of duties in violation
of this provision shall be null and void.

 

    	13

     

    

 

Section
6.05 Amendment. Other than as specifically set forth herein, no amendment, modification, termination, discharge or change
(collectively, “Amendment”) of this Agreement shall be valid and effective, unless the Parties shall unanimously agree
in writing to such Amendment.

 

Section
6.06 Further Assurances. Following the Closing Date each of the Parties shall, and shall cause their respective Affiliates
to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may
be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated herein.

 

Section
6.07No Waiver. No waiver of any provision of this Agreement shall be effective unless it is in writing and signed by
the Party against whom it is asserted, and any such written waiver shall only be applicable to the specific instance to which
it relates and shall not be deemed to be a continuing or future waiver.

 

Section
6.08 Headings. The article and section headings contained in this Agreement are inserted for convenience only and shall
not affect in any way the meaning or interpretation of the Agreement.

 

Section
6.09 Governing Law. This Agreement, and any dispute arising out of, relating to, or in connection with this Agreement,
shall be governed by and construed in accordance with the laws of the State of Nevada, without giving effect to any choice or
conflict of law provision or rule (whether of the State of Nevada or of any other jurisdiction) that would cause the application
of the laws of any jurisdiction other than the State of Nevada.

 

Section
6.10 Specific Performance. The Parties agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed by them in accordance with the terms hereof or were otherwise breached and that each Party
hereto shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches
of the provisions hereof and to enforce specifically the terms and provisions hereof, without the proof of actual damages, in
addition to any other remedy to which they are entitled at law or in equity. Each Party agrees to waive any requirement for the
security or posting of any bond in connection with any such equitable remedy, and agrees that it will not oppose the granting
of an injunction, specific performance or other equitable relief on the basis that (a) any other Party has an adequate remedy
at law, or (b) an award of specific performance is not an appropriate remedy for any reason at law or equity.

 

Section
6.11 Enforcement of the Agreement; Jurisdiction; No Jury Trial.

 

	 	(a)	Subject
    to Section 6.10 and Section 6.12, each of the Parties irrevocably agrees that any legal action or proceeding with respect
    to this Agreement and the rights and obligations arising under this Agreement, or for recognition and enforcement of any judgment
    or arbitral award or resolution in respect of this Agreement, shall be brought and determined exclusively in the courts of
    the State of Florida located in Broward County, Florida or in the event (but only in the event) that such courts do not have
    subject matter jurisdiction over such action or proceeding, in the United States District Court sitting in Broward County,
    Florida (the “Selected Courts”). Each of the Parties hereby irrevocably submits with regard to any such action
    or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the
    Selected Courts and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated
    by this Agreement in any court other than the Selected Courts. Each of the Parties hereby irrevocably waives, and agrees not
    to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement,
    (a) any claim that it is not personally subject to the jurisdiction of the Selected Courts for any reason other than the failure
    to serve in accordance with this Section 6.11; (b) any claim that it or its property is exempt or immune from jurisdiction
    of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior
    to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise); and (c) to the fullest extent
    permitted by law, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum; (ii)
    the venue of such suit, action or proceeding is improper; or (iii) this Agreement, or the subject matter of this Agreement,
    may not be enforced in or by the Selected Courts.

 

    	14

     

    

 

	 	(b)	EACH
    PARTY TO THIS AGREEMENT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH
    PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT, ACTION OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF,
    UNDER, RELATING TO OR IN CONNECTION WITH THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT

 

Section
6.12 Arbitration. Other than as set forth in Section 6.10, any controversy, claim or dispute arising out of or relating
to this Agreement shall be resolved by arbitration in Coconut Creek, Florida pursuant to then-prevailing rules of the American
Arbitration Association. The arbitration shall be conducted by three arbitrators, with one arbitrator selected by Buyer, one selected
by the Company Parties jointly, and the third arbitrator selected by the two arbitrators so selected by the Parties. The arbitrators
shall be bound to follow the applicable Agreement provisions in adjudicating the dispute. It is agreed all Parties that the arbitrators’
decision is final, and that no Party may take any action, judicial or administrative, to overturn such decision. The judgment
rendered by the arbitrators may be entered in the Selected Courts. Each Party will pay its own expenses of arbitration and the
expenses of the arbitrators will be equally shared provided that, if in the opinion of the arbitrators any claim, defense, or
argument raised in the arbitration was unreasonable, the arbitrators may assess all or part of the expenses of any other Party
(including reasonable attorneys’ fees) and of the arbitrators as the arbitrators deem appropriate. The arbitrators may not
award any Party punitive or consequential damages.

 

Section
6.13 Attorneys’ Fees. If any Party hereto is required to engage in litigation against any other Party, either as
plaintiff or as defendant, in order to enforce or defend any rights under this Agreement, and such litigation results in a final
judgment in favor of such Party (“Prevailing Party”), then the party or parties against whom said final judgment is
obtained shall reimburse the Prevailing Party for all direct, indirect or incidental expenses incurred, including, but not limited
to, all attorneys’ fees, court costs and other expenses incurred throughout all negotiations, trials or appeals undertaken
in order to enforce the Prevailing Party’s rights hereunder.

 

Section
6.14 Severability; Expenses. If any term, condition or other provision of this Agreement is determined by a court of competent
jurisdiction to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms, conditions
and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance
of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner
in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the fullest extent
possible. Except as otherwise specifically provided in this Agreement, each Party shall be responsible for the expenses it may
incur in connection with the negotiation, preparation, execution, delivery, performance and enforcement of this Agreement.

 

Section
6.15 Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each Party, and nothing
in this Agreement, express or implied, is intended to confer upon any other person or entity any rights or remedies of any nature
whatsoever under or by reason of this Agreement other than as specifically set forth herein, including, without limitation, in
Article V.

 

Section
6.16 Execution in Counterparts, Electronic Transmission. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original. The signature of any Party which is transmitted by any reliable electronic means such
as, but not limited to, a photocopy, electronically scanned or facsimile machine, for purposes hereof, is to be considered as
an original signature, and the document transmitted is to be considered to have the same binding effect as an original signature
or an original document.

 

[Signatures
appear on following page]

 

    	15

     

    

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the Closing Date.

 

	 	NutraLife Biosciences, Inc. 
	 	 	 
	 	By:	/s/
    Edgar Ward
	 	Name:	Edgar
    Ward
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	Lord Global Corporation
	 	 	 
	 	By:	/s/
    Joseph Frontiere
	 	Name:	Joseph
    Frontiere
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	27 Health, Inc.
	 	 	 
	 	By:	/s/
    Joseph Frontiere
	 	Name:	Joseph
    Frontiere
	 	Title:	Chief
    Executive Officer

 

    	16

     

    

 

Exhibit
A

 

Certificate
of Designations, Preferences and Rights of Series X Convertible Preferred Stock

 

 (Attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]